Toxicological Profile for
Di(2-Ethylhexyl)Phthalate (DEHP)
Draft for Public Comment
December 2019
DISCLAIMER

Use of trade names is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry, the Public Health Service, or the U.S. Department of Health and Human Services.

This information is distributed solely for the purpose of pre dissemination public comment under applicable information quality guidelines. It has not been formally disseminated by the Agency for Toxic Substances and Disease Registry. It does not represent and should not be construed to represent any agency determination or policy.
FOREWORD

This toxicological profile is prepared in accordance with guidelines developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the Federal Register on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for these toxic substances described therein. Each peer-reviewed profile identifies and reviews the key literature that describes a substance's toxicologic properties. Other pertinent literature is also presented, but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile begins with a relevance to public health discussion which would allow a public health professional to make a real-time determination of whether the presence of a particular substance in the environment poses a potential threat to human health. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to the protection of public health are identified by ATSDR and EPA.

Each profile includes the following:

(A) The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a toxic substance to ascertain the levels of significant human exposure for the substance and the associated acute, intermediate, and chronic health effects;

(B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine the levels of exposure that present a significant risk to human health due to acute, intermediate, and chronic duration exposures; and

(C) Where appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are health professionals at the Federal, State, and local levels; interested private sector organizations and groups; and members of the public. ATSDR plans to revise these documents in response to public comments and as additional data become available. Therefore, we encourage comments that will make the toxicological profile series of the greatest use.

Electronic comments may be submitted via: www.regulations.gov. Follow the on-line instructions for submitting comments.

Written comments may also be sent to: Agency for Toxic Substances and Disease Registry
Division of Toxicology and Human Health Sciences
Environmental Toxicology Branch
1600 Clifton Road, N.E.
Mail Stop S102-1
Atlanta, Georgia 30329-4027
The toxicological profiles are developed under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended (CERCLA or Superfund). CERCLA section 104(i)(1) directs the Administrator of ATSDR to “…effectuate and implement the health related authorities” of the statute. This includes the preparation of toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List (NPL) and that pose the most significant potential threat to human health, as determined by ATSDR and the EPA. Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the list. In addition, ATSDR has the authority to prepare toxicological profiles for substances not found at sites on the NPL, in an effort to “…establish and maintain inventory of literature, research, and studies on the health effects of toxic substances” under CERCLA Section 104(i)(1)(B), to respond to requests for consultation under section 104(i)(4), and as otherwise necessary to support the site-specific response actions conducted by ATSDR.

This profile reflects ATSDR’s assessment of all relevant toxicologic testing and information that has been peer-reviewed. Staffs of the Centers for Disease Control and Prevention and other Federal scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel and is being made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.

Patrick N. Breysse, Ph.D., CIH
Director, National Center for Environmental Health and
Agency for Toxic Substances and Disease Registry
Centers for Disease Control and Prevention

***DRAFT FOR PUBLIC COMMENT***
## VERSION HISTORY

<table>
<thead>
<tr>
<th>Date</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>December 2019</td>
<td>Draft for public comment toxicological profile released</td>
</tr>
<tr>
<td>September 2002</td>
<td>Final toxicological profile released</td>
</tr>
<tr>
<td>April 1993</td>
<td>Final toxicological profile released</td>
</tr>
<tr>
<td>June 1989</td>
<td>Final toxicological profile released</td>
</tr>
</tbody>
</table>
CONTRIBUTORS & REVIEWERS

CHEMICAL MANAGER TEAM

Rae T. Benedict, Ph.D. (Lead)  
Sam Keith, M.S., C.H.P.  
Hana Pohl, M.D., Ph.D.  
Mike Fay, Ph.D.  
Heather Carlson-Lynch, M.S., D.A.B.T.  
Julie Melia, Ph.D., D.A.B.T.  
Kimberly Zaccaria, Ph.D., D.A.B.T.  
Courtney Hard, B.A.  
Mario Citra, Ph.D.

ATSDR, Division of Toxicology and Human Health Sciences, Atlanta, GA  
SRC, Inc., North Syracuse, NY

REVIEWERS

Interagency Minimal Risk Level Workgroup:  
Includes ATSDR; National Center for Environmental Health (NCEH); National Institute of Occupational Health and Safety (NIOSH); U.S. Environmental Protection Agency (EPA); National Toxicology Program (NTP).

Additional reviews for science and/or policy:  
ATSDR, Division of Community Health Investigations; ATSDR, Office of Science; NCEH, Division of Laboratory Science; NCEH, Division of Environmental Health Science and Practice; EPA, National Center for Environmental Assessment.

PEER REVIEWERS

1. Tee L. Guidotti, M.D., MPH; Retired Chair of the Department of Environmental and Occupational Health and Director of the Division of Occupational Medicine and Toxicology at George Washington University; Affiliate with Risk Sciences International Inc., Silver Spring, Maryland
2. J. E. Klaunig, Ph.D., Fellow ATS, Fellow IATP; Professor, Environmental Health; Professor, School of Public and Environmental Affairs; Indiana University Bloomington; Bloomington, Indiana
3. Emily S. Barrett, Ph.D.; Associate Professor, Department of Epidemiology; Environmental and Occupational Health Sciences Institute; Rutgers School of Public Health; Piscataway, New Jersey

These experts collectively have knowledge of toxicology, chemistry, and/or health effects. All reviewers were selected in conformity with Section 104(i)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

ATSDR scientists review peer reviewers’ comments and determine whether changes will be made to the profile based on comments. The peer reviewers’ comments and responses to these comments are part of the administrative record for this compound.

The listing of peer reviewers should not be understood to imply their approval of the profile's final content. The responsibility for the content of this profile lies with ATSDR.
# CONTENTS

DISCLAIMER ............................................................................................................................................... ii
FOREWORD .................................................................................................................................................. iii
VERSION HISTORY ........................................................................................................................................... v
CONTRIBUTORS & REVIEWERS ................................................................................................................ vi
CONTENTS ................................................................................................................................................ vii
LIST OF FIGURES ........................................................................................................................................ ix
LIST OF TABLES ......................................................................................................................................... x

CHAPTER 1. RELEVANCE TO PUBLIC HEALTH ................................................................................ 1
  1.1 OVERVIEW AND U.S. EXPOSURES ..................................................................................... 1
  1.2 SUMMARY OF HEALTH EFFECTS ..................................................................................... 3
  1.3 MINIMAL RISK LEVELS (MRLs) ....................................................................................... 10

CHAPTER 2. HEALTH EFFECTS ...................................................................................................... 14
  2.1 INTRODUCTION ..................................................................................................................... 14
  2.2 DEATH ..................................................................................................................................... 70
  2.3 BODY WEIGHT ....................................................................................................................... 71
  2.4 RESPIRATORY ....................................................................................................................... 88
  2.5 CARDIOVASCULAR .............................................................................................................. 91
  2.6 GASTROINTESTINAL .......................................................................................................... 97
  2.7 HEMATOLOGICAL ............................................................................................................... 98
  2.8 MUSCULOSKELETAL .......................................................................................................... 99
  2.9 HEPATIC ................................................................................................................................ 100
  2.10 RENAL .................................................................................................................................. 113
  2.11 DERMAL ............................................................................................................................ 116
  2.12 OCULAR ............................................................................................................................. 117
  2.13 ENDOCRINE ...................................................................................................................... 118
  2.14 IMMUNOLOGICAL ............................................................................................................ 133
  2.15 NEUROLOGICAL .............................................................................................................. 145
  2.16 REPRODUCTIVE .............................................................................................................. 147
  2.17 DEVELOPMENTAL ........................................................................................................... 190
  2.18 OTHER NONCANCER .................................................................................................... 246
  2.19 CANCER ............................................................................................................................ 255
  2.20 GENOTOXICITY ................................................................................................................. 259

CHAPTER 3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL
INTERACTIONS .......................................................................................................................................... 270
  3.1 TOXICOKINETICS ............................................................................................................... 270
  3.1.1 Absorption ........................................................................................................................ 270
  3.1.2 Distribution ....................................................................................................................... 274
  3.1.3 Metabolism ...................................................................................................................... 277
  3.1.4 Excretion .......................................................................................................................... 282
  3.1.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models......... 287
  3.1.6 Animal-to-Human Extrapolations .................................................................................... 292
  3.2 CHILDREN AND OTHER POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE ... 293
  3.3 BIOMARKERS OF EXPOSURE AND EFFECT .................................................................... 298
  3.3.1 Biomarkers of Exposure .................................................................................................. 299
  3.3.2 Biomarkers of Effect ........................................................................................................ 301
  3.4 INTERACTIONS WITH OTHER CHEMICALS ....................................................................... 301

***DRAFT FOR PUBLIC COMMENT***
LIST OF FIGURES

1-1. Health Effects Found in Animals Following Inhalation Exposure to DEHP ........................................ 4

1-2. Health Effects Found in Animals Following Oral Exposure to DEHP ................................................ 5

1-3. Summary of Sensitive Targets of DEHP – Inhalation................................................................. 11

1-4. Summary of Sensitive Targets of DEHP – Oral ........................................................................... 12

2-1. Overview of the Number of Studies Examining DEHP Health Effects .......................................... 18

2-2. Levels of Significant Exposure to DEHP – Inhalation................................................................. 22

2-3. Levels of Significant Exposure to DEHP – Oral ........................................................................... 61

3-1. Metabolic Pathway of DEHP........................................................................................................ 279

5-1. Number of NPL Sites with DEHP Contamination ...................................................................... 312

6-1. Summary of Existing Health Effects Studies on DEHP By Route and Endpoint......................... 373
## LIST OF TABLES

1-1. Minimal Risk Levels (MRLs) for DEHP ................................................................. 13

2-1. Levels of Significant Exposure to DEHP – Inhalation ............................................. 19

2-2. Levels of Significant Exposure to DEHP – Oral ..................................................... 24

2-3. Levels of Significant Exposure to DEHP – Dermal ................................................ 69

2-4. Selected Epidemiological Studies of DEHP Exposure and Body Weight Metrics ....... 72

2-5. Selected Epidemiological Studies of DEHP Exposure and Blood Pressure .............. 92

2-6. Selected Epidemiological Studies of DEHP Exposure and Serum Lipid/Cholesterol Alterations .................................................................................................................. 102

2-7. Summary of Epidemiological Studies of DEHP Exposure and Thyroid Hormone Levels .......... 119

2-8. Selected Epidemiological Studies of DEHP Exposure and Allergy, Asthma, and Atopy ........ 134

2-9. Summary of Epidemiological Studies of DEHP Exposure and Serum Reproductive Hormones or Leydig Cell Functionality in Adult Men .................................................. 149

2-10. Summary of Epidemiological Studies of DEHP Exposure and Sperm Morphology or Motility ................................................................................................................................. 159

2-11. Summary of Epidemiological Studies of DEHP Exposure and Female Reproductive Effects ..... 173

2-12. Summary of Epidemiological Studies of Prenatal DEHP Exposure and Pregnancy Outcomes ........................................................................................................................................ 180

2-13. Summary of Epidemiological Studies of Prenatal DEHP Exposure and Birth Size ............ 192

2-14. Summary of Epidemiological Studies of Prenatal DEHP Exposure and BMI, Waist Circumference, and Fat Mass ..................................................................................................... 197

2-15. Summary of Epidemiological Studies of Prenatal DEHP Exposure and Selected Neurodevelopmental Outcomes .................................................................................................... 209

2-16. Summary of Epidemiological Data on Reproductive Tract Development in Male and Female Infants ...................................................................................................................................... 223

2-17. Selected Epidemiological Studies of DEHP Exposure and Diabetes or Glucose Homeostasis ......................................................... 247

2-18. Genotoxicity of DEHP In Vitro .............................................................................. 260

2-19. Genotoxicity of MEHP In Vitro ............................................................................. 262

2-20. Genotoxicity of DEHP In Vivo .............................................................................. 264
2-21. Genotoxicity of MEHP In Vivo

3-1. Tissue Distribution of [14C] Following an Intravenous Dose of 50 mg/kg [14C]-DEHP in Male Wistar Rats

3-2. Tissue Distribution of [14C] Following an Oral Dose of 500 mg/kg [14C]-DEHP in Male Wistar Rats

3-3. Michaelis-Menten Constants for DEHP Hydrolase Activity in Liver Microsomes

3-4. Comparison of Phthalate Metabolites in Urine Following Dosing with DEHP

3-5. Blood, Serum, or Plasma Elimination Half-Lives ($t_{1/2}$) for DEHP and MEHP

3-6. Urinary Elimination Half-Lives ($t_{1/2}$) for DEHP, MEHP, and Metabolites

4-1. Chemical Identity of DEHP

4-2. Physical and Chemical Properties of DEHP

5-1. Facilities that Produce, Process, or Use DEHP

5-2. Releases to the Environment from Facilities that Produce, Process, or Use DEHP

5-3. Lowest Limit of Detection Based on Standards

5-4. Summary of Environmental Levels of DEHP

5-5. DEHP Levels in Water, Soil, and Air of National Priorities List (NPL) Sites

5-6. Concentration of DEHP in Food

5-7. Concentration DEHP in Categories of Household Waste


<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>5-16.</td>
<td>Types of Industries with Reported TRI Releases</td>
<td>364</td>
</tr>
<tr>
<td>5-17.</td>
<td>FDA Estimates of DEHP Exposures Resulting from Medical Treatments</td>
<td>370</td>
</tr>
<tr>
<td>6-1.</td>
<td>Ongoing Studies on DEHP</td>
<td>379</td>
</tr>
<tr>
<td>7-1.</td>
<td>Regulations and Guidelines Applicable to DEHP</td>
<td>381</td>
</tr>
</tbody>
</table>